<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl2">
 <label>Table 2</label>
 <caption>
  <p>Summary of included studies</p>
 </caption>
 <alt-text id="alttext0025">Table 2</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Study and location</th>
    <th>Design</th>
    <th>Inclusion criteria</th>
    <th>Treatment regimens</th>
    <th>Results—highlights</th>
    <th>Risk of bias
     <xref rid="tbl2fna" ref-type="table-fn">a</xref> and other comments
    </th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td colspan="6">
     <italic>HIV</italic>
    </td>
   </tr>
   <tr>
    <td>Sperber et al., 1995, USA [
     <xref rid="bib17" ref-type="bibr">17</xref>]
    </td>
    <td>Randomized, double-blind, placebo-controlled trial</td>
    <td>HIV-infected patients with CD4+ cell count 200–500/μL and not taking antiretroviral (ART) therapy</td>
    <td>1) HCQ 800 mg/d for 8 weeks (
     <italic>n</italic> = 20) or 2) Placebo for same duration (
     <italic>n</italic> = 20)
    </td>
    <td>Significant decrease in viral load in HCQ group (p 0.022)
     <break/>No change in absolute CD4+ cell count
    </td>
    <td>Method of sample size calculation or randomization is not given
     <break/>HCQ was well tolerated
    </td>
   </tr>
   <tr>
    <td>Sperber et al., 1997, USA [
     <xref rid="bib18" ref-type="bibr">18</xref>]
    </td>
    <td>Randomized, double-blind, masked trial</td>
    <td>HIV-infected patients with CD4+ cell count 200–500/μL</td>
    <td>1) HCQ 800 mg/d for 16 weeks (
     <italic>n</italic> = 35) or 2) Zidovudine 500 mg/d for same duration (
     <italic>n</italic> = 37)
    </td>
    <td>Significant decrease in viral load in both HCQ (p 0.02) and zidovudine groups (p 0.001)
     <break/>No change in absolute CD4+ cell count
    </td>
    <td>Method of sample size calculation or randomization not given</td>
   </tr>
   <tr>
    <td>Paton et al., 2012, United Kingdom [
     <xref rid="bib20" ref-type="bibr">20</xref>]
    </td>
    <td>Randomized, double-blind, placebo-controlled trial</td>
    <td>HIV-infected asymptomatic patients, not on ART, CD4+ count&gt; 400 cells/μL</td>
    <td>HCQ 400 mg/d (
     <italic>n</italic> = 42) or placebo (
     <italic>n</italic> = 41) for 48 weeks
    </td>
    <td>No significant difference in CD8+ cell activation
     <break/>Greater decline of CD4+ cell count in HCQ group (p 0.03)
     <break/>Greater increase in HIV viral load in HCQ group (p &lt; 0.003)
    </td>
    <td>High risk of attrition bias – 31% attrition rate
     <break/>HCQ was well tolerated despite more flu-like episodes
    </td>
   </tr>
   <tr>
    <td>Paton et al., 2002, Singapore [
     <xref rid="bib24" ref-type="bibr">24</xref>]
    </td>
    <td>Non-controlled prospective study</td>
    <td>HIV-infected patients with a viral load &lt;10
     <sup>5</sup> copies/μL and CD4+ cell count &gt; 150/μL
    </td>
    <td>HCQ 200 mg/bid, hydroxyurea 500 mg/bid and didanoside 125–200 mg/bid according to bodyweight for 48 weeks (
     <italic>n</italic> = 22)
    </td>
    <td>Decline in viral load by an average of 1.3 logs with sustained CD4+ cell level</td>
    <td>Neutropenia and elevated amylase levels noted in a majority of patients with two severe adverse events</td>
   </tr>
   <tr>
    <td>Piconi et al., 2011, Italy [
     <xref rid="bib23" ref-type="bibr">23</xref>]
    </td>
    <td>Non-controlled prospective study</td>
    <td>HIV-infected, adult, immunological non-responders (CD4+ cell count &lt;200/μL or &lt;5% increase in preceding 12 months)</td>
    <td>HCQ 400 mg/d for 6 months (
     <italic>n</italic> = 20)
    </td>
    <td>No significant change in absolute CD4+ cell count
     <break/>Significant reduction in Ki67-expressing (activated) CD4+ cells
     <break/>Significant reduction in TLR-2-, TLR-4- and TLR-5-expressing CD14+ cells
     <break/>Significant increase in TLR-2- and TLR-4-expressing regulatory T cells
     <break/>Plasma IL-6 was significantly decreased
     <break/>Significant reduction in plasma lipopolysaccharide (LPS) levels
    </td>
    <td>Observations supportive of an immunomodulatory effect of HCQ to reduce immune activation in HIV</td>
   </tr>
   <tr>
    <td>Engchanil et al., 2006, Thailand [
     <xref rid="bib19" ref-type="bibr">19</xref>]
    </td>
    <td>Prospective, randomized open-label clinical trial</td>
    <td>HIV-infected children (&lt;14 years of age); CDC clinical category A,B or C; CDC immunological category 2 or 3</td>
    <td>1) Zidovudine (ZDV)+ didanosine (ddI) (
     <italic>n</italic> = 25)
     <break/>2) ZDV + ddI + CQ (
     <italic>n</italic> = 30, includes nine children where CQ was added to an existing ZDV + ddI therapy)
     <break/>ZDV 150 mg/m
     <sup>2</sup> body surface area/dose every 8 h; ddI 90–100 mg/m
     <sup>2</sup> body surface area/dose every 12 h; and CQ 4 mg/kg/dose daily
     <break/>Treatment continued for 24 weeks
    </td>
    <td>No significant difference in the drop of viral load or increase in CD4+ cell count between the groups without CQ and with CQ</td>
    <td>High risk of performance and detection bias due to open-label design
     <break/>High risk of attrition bias – 22% attrition rate
     <break/>More gastrointestinal adverse events noted in the group with CQ
    </td>
   </tr>
   <tr>
    <td>Jacobson et al., 2016, USA [
     <xref rid="bib21" ref-type="bibr">21</xref>]
    </td>
    <td>Randomized, double-blind, placebo-controlled cross-over trial</td>
    <td>Two cohorts: a) off ART for at least 6 months, HIV RNA &gt;1000 copies/mL, CD4+ count &gt;400/μL
     <break/>b) on ART for at least 24 months, HIV RNA level undetectable, CD4+ count &gt;350/μL
    </td>
    <td>Each cohort had two arms that received either CQ 250 mg (150 mg base) per day for 12 weeks followed by placebo for 12 weeks or vice versa
     <break/>37 patients were on ART, 33 patients were off ART
    </td>
    <td>No significant immune activation of CD4+ and CD8+ cells in off-ART cohort
     <break/>Significant reduction in activated CD8+ cells but not in CD4+ cells with CQ in the on-ART cohort. CQ also led to an increase in viral RNA load
    </td>
    <td>High risk of attrition bias – 13% attrition rate
     <break/>No significant increase in adverse events reported for CQ
    </td>
   </tr>
   <tr>
    <td>Murray et al., 2010, USA [
     <xref rid="bib22" ref-type="bibr">22</xref>]
    </td>
    <td>Randomized, double-blind, placebo-controlled trial</td>
    <td>HIV-infected adults with CD4+ counts &gt;250/μL and either ART naïve or off ART for 16 months</td>
    <td>250 mg (150 mg base) CQ daily (
     <italic>n</italic> = 6, CQ 500 mg daily (
     <italic>n</italic> = 3), or placebo (
     <italic>n</italic> = 4) for 2 months
    </td>
    <td>Percentage of CD38+ and HLA DR + CD8 cells were significantly reduced with CQ treatment (p 0.016)</td>
    <td>Small clinical trial with 3–6 patients per trial arm. Method for sample size calculation is not mentioned
     <break/>CQ may reduce immune activation in HIV
    </td>
   </tr>
   <tr>
    <td colspan="6">
     <italic>HCV</italic>
    </td>
   </tr>
   <tr>
    <td>Helal et al., 2016, Egypt [
     <xref rid="bib27" ref-type="bibr">27</xref>]
    </td>
    <td>Randomized, prospective, single-blind, controlled study</td>
    <td>Patients with chronic active HCV (genotype 4) infection with chronic hepatitis on liver biopsy but without decompensated liver disease</td>
    <td>Group 1: pegylated interferon (IFN) 160 μg subcutaneously weekly + oral ribavirin 1000–1200 md/d for 12 weeks (
     <italic>n</italic> = 60)
     <break/>Group 2: as above + 400 mg/d HCQ (
     <italic>n</italic> = 60)
    </td>
    <td>Significantly higher rate of early virological response in group 2 (p 0.011)</td>
    <td>High risk of selection bias—method of allocation concealment not clear
     <break/>High risk of performance or detection bias—single-blind study design
     <break/>No additional adverse events due to HCQ
    </td>
   </tr>
   <tr>
    <td>Peymani et al., 2016, Iran [
     <xref rid="bib26" ref-type="bibr">26</xref>]
    </td>
    <td>Randomized, triple-blind, placebo-controlled pilot trial</td>
    <td>Patients with HCV (genotype 1) not responding to standard IFN and ribavirin therapy</td>
    <td>CQ 150 mg (base)/d for 8 weeks or placebo (
     <italic>n</italic> = 10)
    </td>
    <td>Significant decrease in viral RNA (p 0.04) after 8 weeks</td>
    <td>This is a small clinical trial and method of sample size calculation is unclear
     <break/>Rebound of viral RNA noted after stopping CQ
    </td>
   </tr>
   <tr>
    <td colspan="6">
     <italic>Dengue</italic>
    </td>
   </tr>
   <tr>
    <td>Tricou et al., 2010, Vietnam [
     <xref rid="bib28" ref-type="bibr">28</xref>]
    </td>
    <td>Randomized, double-blind, placebo-controlled trial</td>
    <td>Patients with clinically suspected dengue, enrolled within first 3 days of fever and later confirmed with diagnostic testing (NS1 antigen test and RT-PCR)</td>
    <td>Group 1: CQ 600 mg/d (base) for 2 days and 300 mg for 1 day (
     <italic>n</italic> = 153)
     <break/>Group 2: placebo (
     <italic>n</italic> = 153)
    </td>
    <td>No statistically significant difference in clearance of antigenaemia (NS1), clearance of viraemia or incidence of dengue haemorrhagic fever</td>
    <td>Low risk of bias
     <break/>CQ group had significantly more adverse events
    </td>
   </tr>
   <tr>
    <td>Borges et al., 2013, Brazil [
     <xref rid="bib29" ref-type="bibr">29</xref>]
    </td>
    <td>Randomized double-blind study</td>
    <td>Patients with clinically suspected dengue, later confirmed with diagnostic testing</td>
    <td>Group 1: CQ 600 mg (base) for 3 days (
     <italic>n</italic> = 19)
     <break/>Group 2: placebo (
     <italic>n</italic> = 18)
    </td>
    <td>No statistically significant difference in the duration of fever</td>
    <td>High risk of bias as most recruited patients were not confirmed to have dengue. Sample size calculation is unclear. Subjective improvement of symptoms was noted with CQ which reversed upon ceasing the regimen</td>
   </tr>
   <tr>
    <td colspan="6">
     <italic>Chikungunya</italic>
    </td>
   </tr>
   <tr>
    <td>De Lamballerie et al. French Reunion Islands 2008 [
     <xref rid="bib30" ref-type="bibr">30</xref>]
    </td>
    <td>Randomized, double-blind, placebo-controlled trial</td>
    <td>Patients with confirmed acute chikungunya infection by RT-PCR and seroconversion between day 1 and 16 of illness</td>
    <td>Group 1: CQ 600 mg/d (base) for 3 days, 300 mg/d for 2 days (
     <italic>n</italic> = 27)
     <break/>Group 2: placebo (
     <italic>n</italic> = 27)
    </td>
    <td>No statistically significant difference in fever clearance time or viraemia clearance time</td>
    <td>Patients in CQ group were more likely to complain of persistent symptoms at day 200. However, they might have had more severe disease at enrolment as revealed later by an analysis of inflammatory markers of stored blood samples—high risk of selection bias</td>
   </tr>
   <tr>
    <td colspan="6">
     <italic>COVID-19</italic>
    </td>
   </tr>
   <tr>
    <td>Chen et al. China, 2020 [
     <xref rid="bib36" ref-type="bibr">36</xref>]
    </td>
    <td>Randomized controlled clinical trial</td>
    <td>Adult patients with virologically confirmed (RT-PCR) mild COVID-19 infection</td>
    <td>Group 1: HCQ 400 mg/d for 5 days plus ‘standard treatment’ (
     <italic>n</italic> = 15)
     <break/>Group 2: ‘standard treatment’ (
     <italic>n</italic> = 15)
    </td>
    <td>No statistically significant difference in clearance of viraemia by day 7, fever clearance time or total duration of hospitalization</td>
    <td>Article is published in Mandarin
     <break/>Only the English abstract was reviewed
     <break/>Unable to assess risk of bias
    </td>
   </tr>
   <tr>
    <td>Gautret et al. France, 2020 [
     <xref rid="bib35" ref-type="bibr">35</xref>]
    </td>
    <td>Open-label, non-randomized, controlled trial</td>
    <td>Adult patients with virologically confirmed (RT-PCR) COVID-19 infection as test group
     <break/>Similar patients treated at a different institution or those refusing HCQ treatment at the same institute
    </td>
    <td>Group 1: HCQ 600 mg/d for 10 days (
     <italic>n</italic> = 26)
     <break/>Group 2: no HCQ treatment (
     <italic>n</italic> = 16)
    </td>
    <td>Statistically significant rate of clearance of viraemia by day 6 of illness (70% in HCQ group versus 12.5% in placebo group, p 0.001)</td>
    <td>Serious risks of bias due to open-label design, small sample size, non-random allocation and confounding effects due to recruiting control patients from a different institution, azithromycin administration in some patients only, and baseline age difference in test and control groups</td>
   </tr>
   <tr>
    <td>Chen et al. China, 2020 [
     <xref rid="bib38" ref-type="bibr">38</xref>]
    </td>
    <td>Randomized double-blind controlled clinical trial</td>
    <td>Adult patients with virologically confirmed (RT-PCR) mild COVID-19 infection</td>
    <td>Group 1: HCQ 400 mg/d for 5 days plus ‘standard treatment’ (
     <italic>n</italic> = 31)
     <break/>Group 2: ‘standard treatment’ (
     <italic>n</italic> = 31)
    </td>
    <td>Statistically significant faster fever recovery and cough relief in HCQ group</td>
    <td>This was a non-peer reviewed preprint
     <break/>High risk of reporting bias—the details of statistical interpretation and effect size are not explained
     <break/>The ‘standard treatment’ according to authors included antibiotics, antivirals, steroids and immunoglobulins
     <break/>Until more details are provided, the results cannot be interpreted
    </td>
   </tr>
   <tr>
    <td>Tang et al. China, 2020 [
     <xref rid="bib37" ref-type="bibr">37</xref>]
    </td>
    <td>Open-label randomized trial</td>
    <td>Adult patients with virologically confirmed (RT-PCR) mostly mild COVID-19 infection</td>
    <td>Group 1: HCQ 200 mg/d for 3 days followed by 800 mg/d for 14–21 days + supportive care
     <break/>Group 2: supportive care only
    </td>
    <td>No statistically significant difference in the proportion of aviraemic patients by day 28, time to aviraemia, or symptom resolution by day 28</td>
    <td>This was a non-peer reviewed preprint
     <break/>High risk of performance and detection bias
    </td>
   </tr>
   <tr>
    <td>Huang et al. China, 2020 [
     <xref rid="bib40" ref-type="bibr">40</xref>]
    </td>
    <td>Randomized controlled clinical trial (open label?)</td>
    <td>Adult patients with virologically confirmed (RT-PCR) COVID-19 infection</td>
    <td>Group 1: CQ 600 mg base/d for 10 days
     <break/>Group 2: lopinavir/ritonavir 400/100 mg orally twice daily for 10 days
    </td>
    <td>No statistically significant difference in viraemia clearance by day 14
     <break/>Faster radiological resolution and reduced hospital stay in CQ group
    </td>
    <td>It is not clear whether this was a double-blind study and, if not, there is a high risk of detection and performance bias
     <break/>Method of sample size calculation is unclear
    </td>
   </tr>
   <tr>
    <td>Borba et al. Brazil, 2020 [
     <xref rid="bib41" ref-type="bibr">41</xref>]
    </td>
    <td>Randomized controlled double-blind study</td>
    <td>Adult patients with clinically suspected COVID-19 infection</td>
    <td>Group 1: CQ 1200 mg base/d for 10 days
     <break/>Group 2: CQ 900 mg base on day 1 and 45 0mg base/d for 4 days
    </td>
    <td>Significantly higher mortality in high-dose group by day 13 (15% versus 39%)</td>
    <td>Study terminated due to safety concerns—risk of bias not evaluated</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>ART, antiretroviral therapy; CQ, chloroquine; HCQ, hydroxychloroquine.</p>
  </fn>
 </table-wrap-foot>
 <table-wrap-foot>
  <fn id="tbl2fna">
   <label>a</label>
   <p id="ntpara0010">Risk of bias not assessed for uncontrolled studies as results from these studies were not used to grade evidence. For non-randomized trials with more than one intervention, risk of bias assessed with ROBINS-I tool.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
